TAPP Online Education Website is for the use of Australian and
New Zealand Healthcare Professionals only. To gain access please login or register.

Contact Us

Click here to contact us

Biogen Australia Pty Ltd

ABN 30 095 760 115
Level 3, 123 Epping Rd
North Ryde NSW 2113

Ph: (02) 8875 3900
Fx: (02) 9889 1160
Medical Information:
1800 852 289
(Mon–Fri EST 9 am–5 pm)

Biogen NZ Limited

54 Carbine Road
Mount Wellington
Auckland, New Zealand

Medical Information (NZ):
0800 852 289
(Mon–Fri 11 am–7 pm)

Please report all suspected adverse events

Australia:
Email: pvasiapacific@biogen.com
Ph: 1800 852 289
or Sydney office (02) 8875 3900
(Mon–Fri EST 9 am–5 pm)

New Zealand:
Email: medinfo-aunz@biogen.com
Ph: 0800 852 289

TAPP Online

Welcome to the TYSABRI®Australasian Prescribing Program (TAPP) training. TYSABRI® (natalizumab) was approved by the Therapeutic Goods Administration (TGA) on 30 October 2006. The conditions for granting marketing approval include the compulsory registration and education of neurologists, pharmacies and infusion centres in Australia. This training program is also available to healthcare professionals in New Zealand.

TAPP Education Program

This program is an educational platform for neurologists and other healthcare professionals.

TAPP is designed to:

  • Ensure that those patients most likely to benefit from treatment receive TYSABRI.
  • Assist neurologists to appropriately assess the benefit/risk balance for each of their patients.
  • Ensure that TYSABRI is discontinued earlier rather than later if symptoms and/or signs appear consistent with PML.

TAPP consists of:

  • Neurologists - compulsory prescribing program.
  • Pharmacy and infusion centre staff - compulsory training focusing on dispensing, administration and patient monitoring.
  • All Australian trained Healthcare Professionals to be recorded in a dedicated database (TAPP database) as per TGA reporting requirements.
  • Safety Updates and educational resources including:
  • TYSABRI approved Product Information;

  • TYSABRI Consumer Medicine Information;

  • TYSABRI PBS Authority Information;

  • Process for requesting various medical tests for TYSABRI patients (anti-JCV antibody, anti-natalizumab antibody,
    JC Viral DNA testing)

  • PML Identification and Response brochure

The TAPP database has been custom-made for the TYSABRI Australasian Prescribing Program. The main objective of the database is to manage the commitments Biogen has made to the TGA, which are:

  • Rollout and tracking of training requirements for Healthcare Professionals.

TAPP will focus on clinical monitoring by Healthcare Professionals as the most appropriate risk management approach for treatment of relapsing remitting multiple sclerosis patients with TYSABRI.